Xilio Therapeutics, Inc. (XLO) Misses Q1 EPS by 37c

Xilio Therapeutics, Inc. (NASDAQ: XLO) reported Q1 EPS of ($0.18), $0.37 worse than the analyst estimate of $0.19.

For earnings history and earnings-related data on Xilio Therapeutics, Inc. (XLO) click here.

You May Also Be Interested In

• Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
• Bernstein SocGen Group Reiterates Outperform Rating on SLB (SLB)
• Callaway Golf (CALY) PT Raised to $20 at Truist Securities